Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus

Pediatric Diabetes

Volumn 10, Issue 4, 2009, Pages 269-277

  Stringer, Danielle M ^a   Sellers, Elizabeth A C ^a   Burr, Laura L ^a   Taylor, Carla G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adipokines; CVD; First Nation; Obesity; T2DM

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADOLESCENT; ANTIOXIDANTS; BIOLOGICAL MARKERS; CANADA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION MEDIATORS; OBESITY; OXIDATIVE STRESS; RISK FACTORS;

EID: 66649118881     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00473.x     Document Type: Article

References (51)

1. Sheilds M. Overweight Canadian children and adolescents. Nutrition: findings from the Canadian Community Health Survey [article on-line]. 2005 (available from http://www.statcan.ca/english/research/82-620-MIE/ 2005001/articles/child/cobesity.htm). Accessed 10 January 2006.
2. Felber JP, Acheson KJ, Tappy L. From Obesity to Diabetes. Chichester: John Wiley and Sons, 1993.
3. Young TK, Reading J, Elias B, O'Neil JD. Type 2 diabetes mellitus in Canada's First Nations: Status of an epidemic in progress. Can Med Assoc J 2000: 163: 561-566.
4. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endocrinol Metab 2000: 13: 1395-1402.
5. Fagot-Campagna A, Knowler W, Pettitt D. Type 2 diabetes in Pima Indian children: Cardiovascular risk factors at diagnosis and 10 years later. Diabetes 1998: 47: A605 (Abstract).
6. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004: 350: 1387-1397.
7. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006: 17: 502-509.
8. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003: 108: 736-740.
9. Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004: 314: 415-419.
10. Bhagar K, Vallance P. Inflammatory cytokines impairs endothelium-dependent dilation in human veins in vivo. Circulation 1997: 96: 3042-3047.
11. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001: 108: 1533-1540.
12. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002: 287: 1706-1709.
13. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E deficient mice. Circulation 2002: 106: 2767-2770.
14. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkappaB signaling through a cAMP dependent pathway. Circulation 2000: 102: 1296-1301.
15. Brown AA, Hu FB. Dietary modulation of endothelial function. Am J Clin Nutr 2001: 73: 673-686.
16. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006: 83: 1477S-1482S.
17. Lindmark S, Buren J, Eriksson JW. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: Potential impact for glucotoxicity in vivo. Clin Endocrinol 2006: 65: 301-309.
18. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (Fizz3) protein is increased in obese humans. J Clin Endocrinol Metab 2003: 88: 5452-5455.
19. Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005: 113: 534-537.
20. Canadian Diabetes Association Clinical Practice Guideline Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003: 27: S1-S153.
21. Dean H. Diagnostic criteria for non-insulin dependent diabetes in youth (Niddm-y). Clin Pediatr 1998: 37: 67-79.
22. Venner AA, Lyon ME, Doyle-Baker PK. Leptin: A potential biomarker for childhood obesity? Clin Biochem 2006: 39: 1047-1056.
23. Sepilian VP, Crochet JR, Nagamani M. Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens. Fertil Steril 2006: 85: 1441-1447.
24. Hibbeln JR, Nieminen LRG, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: Estimations considering worldwide diversity. Am J Clin Nutr 2006: 83: 1483-1493.
25. Noto A, Zahradka P, Yurkova N et al. Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats. Lipids 2006: 41: 179-188.
26. Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey SJ. Childhood obesity and adult cardiovascular mortality: A 57-year follow-up study based on the Body Orr cohort. Am J Clin Nutr 1998: 67: 1111-1118.
27. Berenson GS, Srinivasan SR, Bao W, Newman WB, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998: 338: 1650-1656.
28. Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA. C-reactive protein: A family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006: 47: 212-222.
29. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 2003: 108: 2317-2322.
30. Lui J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJG. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity 2006: 14: 500-507.
31. Kapiotis S, Holzer G, Schaller G et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 2006: 26: 2541-2546.
32. Retnakaran R, Zinman B, Connely PW, Harris SB, Hanley AJG. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr 2006: 148: 176-182.
33. Sellers EAC, Dean HJ, Flett B, Divikar A, Soni R, Saurette R. Carotid intima-media thickness and other cardiovascular risk factors in youth with type 2 diabetes mellitus. Can J Diabetes 2005: 29: 271 (Abstract A36).
34. Retnakaran R, Hanley AJ, Connelly PW, Harris SB, Zinman B. Elevated C-reactive protein in Native Canadian children: An ominous early complication of childhood obesity. Diabetes Obes Metab 2006: 8: 483-491.
35. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003: 107: 499-511.
36. Reinehr T, Kratzsch J, Kiess W, Andler W. Circulating soluble leptin receptor, leptin, and insulin resistance before and after weight loss in obese children. Int J Obes 2005: 29: 1230-1235.
37. Cinaz P, Bideci A, Camurdan MO, Guven A, Gonen S. Leptin and soluble leptin receptor levels in obese children in fasting and satiety states. J Pediatr Endocrinol Metab 2005: 87: 4587-4594.
38. Couillard C, Ruel G, Archer WR et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab 2005: 90: 6454-6459.
39. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: A prospective cohort study. Diabetologia 2007: 50: 1178-1185.
40. Janowska J, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M. Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism 2006: 55: 1495-1499.
41. Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm 2006: 2006: 1-7.
42. Mcfarlin BK, Johnston CA, Tyler C et al. Inflammatory markers are elevated in overweight Mexican-American children. Int J Pediatr Obes 2007: 2: 235-241.
43. Gerber M, Boettner A, Seidel B et al. Serum resistin levels of obese and lean children and adolescents: Biochemical analysis and clinical relevance. J Clin Endocrinol Metab 2005: 90: 4503-4509.
44. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: Mechanisms and functional implications. Biochem J 2008: 409: 623-633.
45. Beauloye V, Zech F, Tran Thi Mong H, Clapuyt P, Maes M, Brichard SM. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007: 92: 3025-3032.
46. Cruz M, Garcia-Macedo R, Garcia-Valero M et al. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 2004: 27: 1451-1453.
47. Satoh N, Naruse M, Usui T et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004: 27: 2488-2489.
48. Molnar D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord 2004: 28: 1197-1202.
49. Myara I, Alamowitch C, Michel O et al. Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 2003: 11: 112-120.
50. Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients. Diabet Med 2003: 20: 563-567.
51. Moilanen T, Rasanen L, Viikan J, Akerblom HK, Nikkari T. Correlation of serum fatty acid composition with dietary intake data in children and young adults. Ann Med 1992: 24: 67-70.